| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H12O4 |
| Molecular Weight | 256.2534 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)[C@@H]2CC(=O)C3=CC=C(O)C=C3O2
InChI
InChIKey=FURUXTVZLHCCNA-AWEZNQCLSA-N
InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2/t14-/m0/s1
| Molecular Formula | C15H12O4 |
| Molecular Weight | 256.2534 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Liquiritigenin is a plant-derived flavonoid isolated from the roots of plants belonging to licorice species (Glycyrrhiza uralensis, Glycyrrhiza glabra, Glycyrrhiza inflate etc) and is available in common foods and alternative medicine. Liquiritigenin is one of the major active compounds of MF101, selective ER-beta agonist herbal extract of 22 botanical ingredients originally tested for reducing the frequency and severity of menopausal hot flashes. At sufficient concentrations, liquiritigenin is also a partial agonist of ER-alpha but has a 20-fold higher affinity for ER-beta than for ER-alpha. Several studies showed that liquiritigenin exerts cytoprotective effects against heavy metal-induced toxicity in cultured hepatocytes, has protective effects against liver injuries induced by acetaminophen and buthione sulfoximine in rats and has an anti-inflammatory effect in macrophages suggesting its potential therapeutic use for liver diseases. Liquiritigenin inhibits the activity of MAO A and B in rat brain mitochondria and displayed favorable properties as a specific transient receptor potential melastatin 3 (TRPM3) blocker. Anti-hepatocellular carcinoma effects of liquiritigenin are related to its modulation of the activations of mitogen-activated protein kinase (MAPKs) and was discovered, that this compound is a potential therapeutic agent for hepatocellular carcinoma treatment.
CNS Activity
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
4.5 g/day (dry weight of extract) of MF101 (Liquiritigeni is one of the major active compounds of MF101), 9.0 g/day (dry weight of extract) of MF101 for 12 weeks in healthy postmenopausal women experiencing at least 5 hot flashes per day or 35 hot flashes per week.
Route of Administration:
Oral
Liquiritigenin was added in final concentrations of 10*(−11) –10*(−5) M every 48–120 hours to human breast cancer cell lines HCC1806 and HCC1937. Proliferation was determined by a colorimetric assay. Changes in viability were used as marker for proliferation. Treatment with liquiritigenin reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus also treatment with liquiritigenin resulted in a significant decrease of CXCR4 protein expression
Showing 1 to 5 of 7 entries
